Dalfampridine and Urinary retention - a phase IV clinical study of FDA data

Summary:

Urinary retention is reported as a side effect among people who take Dalfampridine (dalfampridine), especially for people who are male, 50-59 old, have been taking the drug for < 1 month also take Baclofen, and have Multiple sclerosis.

The phase IV clinical study analyzes which people have Urinary retention when taking Dalfampridine. It is created by eHealthMe based on reports of 9,652 people who have side effects when taking Dalfampridine from the FDA, and is updated regularly.

What is Dalfampridine?

Dalfampridine has active ingredients of dalfampridine. eHealthMe is studying from 9,658 Dalfampridine users. Check the latest studies of Dalfampridine.

What is Urinary retention?

Urinary retention (the inability to completely or partially empty the bladder) is found to be associated with 1,570 drugs and 1,737 conditions by eHealthMe. Check the latest studies of Urinary retention.

On Jul, 12, 2026

9,652 people reported to have side effects when taking Dalfampridine.
Among them, 80 people (0.83%) have Urinary retention.

Could Dalfampridine cause Urinary retention?

Among these 80 people:

How long have people been on Dalfampridine when they have Urinary retention? *

What is the gender of people who have Urinary retention when taking Dalfampridine? *

female: 49.35 %
male: 50.65 %

What is the age of people who have Urinary retention when taking Dalfampridine? *

What are other drugs people take besides Dalfampridine? *

What are other side effects people have besides Urinary retention? *

Fatigue (feeling of tiredness): 37 people, 46.25%
Fall: 33 people, 41.25%
Gait Disturbance: 26 people, 32.50%
Weakness: 24 people, 30.00%
Urinary Tract Infection: 24 people, 30.00%
Constipation: 24 people, 30.00%
Joint Pain: 23 people, 28.75%
Neuralgia (pain in one or more nerves): 22 people, 27.50%
Hypoaesthesia (reduced sense of touch or sensation): 21 people, 26.25%
Muscle Spasticity (tight or stiff muscles and an inability to control those muscles): 21 people, 26.25%

What are the existing conditions these people have? *

Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 32 people, 40.00%
Secondary Progressive Multiple Sclerosis (a stage of ms which comes after relapsing remitting ms in many cases): 19 people, 23.75%
Gait Disturbance: 19 people, 23.75%
Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 16 people, 20.00%
Pain: 15 people, 18.75%
Micturition Urgency (urgency to pass the urine): 14 people, 17.50%
Muscle Spasms (muscle contraction): 12 people, 15.00%
Neuralgia (pain in one or more nerves): 11 people, 13.75%
Urinary Tract Infection: 9 people, 11.25%
Primary Progressive Multiple Sclerosis (primary progressive inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 9 people, 11.25%

* Approximation only. Some reports may have incomplete information.

Do you take Dalfampridine and have Urinary retention?

- Check whether Urinary retention is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Dalfampridine:

Dalfampridine (9,658 reports)

Browse all side effects of Dalfampridine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Urinary retention:

Urinary retention (1,570 drugs)

Browse all the conditions that are associated with Urinary retention:

Urinary retention (1,737 conditions)

Related publications that referenced our studies

Schattner A, Al-Bewerat A, "Levetiracetam (Keppra), urinary retention and literature search", A fatty cause of renal failure; what is your diagnosis?, 2016 Oct .
Schattner A, Al-Bewerat A, "Levetiracetam (Keppra), urinary retention and literature search", A fatty cause of renal failure; what is your diagnosis?, 2016 Oct .

How the study uses the data?

The study uses data from the FDA. It is based on dalfampridine (the active ingredients of Dalfampridine) and Dalfampridine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.